MYC and acute myeloid leukemia: In contrast to the BET inhibitor (+)‐JQ1, a well‐known c‐Myc transcription inhibitor that is being tested in clinic,[48] exhibits no obvious effect against c‐Myc overexpressing AML MOLM‐13 cells, our study demonstrated that single‐agent WBC100 could potently regress c‐Myc overexpressing AML MOLM‐13 cells, while sparing normal tissues at safe doses.